Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders

Alzheimer's Disease
 
 
Academic Press
  • 1. Auflage
  • |
  • erschienen am 20. September 2016
  • |
  • 316 Seiten
 
E-Book | ePUB mit Adobe DRM | Systemvoraussetzungen
E-Book | PDF mit Adobe DRM | Systemvoraussetzungen
978-0-12-802811-7 (ISBN)
 

Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer's Disease examines the drug discovery process for neurodegenerative diseases by focusing specifically on Alzheimer's Disease and illustrating the paradigm necessary to ensure future research and treatment success.

The book explores diagnosis, epidemiology, drug discovery strategies, current therapeutics, and much more to provide a holistic approach to the discovery, development, and treatment of Alzheimer's Disease. Through its coverage of the latest research in targeted drug design, preclinical studies, and mouse and rat models, the book is a must-have resource for all pharmaceutical scientists, pharmacologists, neuroscientists, and clinical researchers working in this area. It illustrates why these drugs tend to fail at the clinical stage, and examines Alzheimer's Disease within the overall context of improving the drug discovery process for the treatment of other neurodegenerative disorders.


  • Provides a compilation of chemical considerations required in drug discovery for the treatment of neurodegenerative disorders
  • Examines different classes of compounds currently being used in discovery and development stages
  • Explores in vitro and in vivo models with respect to their ability to translate these models to human conditions
  • Distills the most significant information across multiple areas of Alzheimer's disease research to provide a single, comprehensive, and balanced resource
  • Englisch
  • San Diego
  • |
  • USA
Elsevier Science
  • 4,71 MB
978-0-12-802811-7 (9780128028117)
0128028114 (0128028114)
weitere Ausgaben werden ermittelt
  • Front Cover
  • DRUG DISCOVERY APPROACHES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
  • DRUG DISCOVERY APPROACHES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
  • Copyright
  • Dedication
  • Contents
  • List of Contributors
  • Foreword
  • Preface
  • Acknowledgments
  • 1 - Neurodegenerative Disorders: Why Do We Need New Therapies?
  • INTRODUCTION
  • CLINICAL FEATURES OF COMMON NEURODEGENERATIVE DISORDERS
  • PATHOLOGICAL FEATURES OF COMMON NEURODEGENERATIVE DISORDERS
  • CURRENT TREATMENT OPTIONS
  • COMMON MECHANISMS IMPLICATED IN NEURODEGENERATION
  • Mitochondrial Dysfunction
  • Protein Aggregation and Clearance
  • Prion-Like Spread
  • Inflammation
  • GOALS FOR NEW DRUG THERAPIES FOR NEURODEGENERATION
  • 2 - Cognitive and Functional Considerations in Alzheimer's Disease Diagnosis
  • DIAGNOSIS OF ALZHEIMER'S DISEASE
  • DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT
  • Functional Measures and Alzheimer's?Disease and Mild Cognitive?Impairment Diagnosis
  • Cognitive Measures and Alzheimer's?Disease and Mild Cognitive?Impairment Diagnosis
  • DIAGNOSIS OF PRECLINICAL ALZHEIMER'S?DISEASE
  • FUTURE DIRECTIONS FOR DIAGNOSIS
  • 3 - National Plan and Resources to Address Alzheimer's Disease
  • NATIONAL ALZHEIMER'S PROJECT ACT
  • NIH MEETING: ALZHEIMER'S DISEASE?RESEARCH SUMMIT 2012: PATH TO?TREATMENT AND PREVENTION?(MAY 14-15, 2012)
  • NIH MEETING: ALZHEIMER'S DISEASE-RELATED DEMENTIAS: RESEARCH CHALLENGES AND OPPORTUNITIES (MAY 1-2, 2013)
  • NIH MEETING: ALZHEIMER'S DISEASE?RESEARCH SUMMIT 2015: PATH TO?TREATMENT AND PREVENTION?(FEBRUARY 9-10, 2015)
  • ALZHEIMER'S DISEASE CENTERS
  • NATIONAL ALZHEIMER'S COORDINATING?CENTER
  • NATIONAL CELL REPOSITORY FOR?ALZHEIMER'S DISEASE
  • ALZHEIMER'S DISEASE COOPERATIVE STUDY
  • ALZHEIMER'S DISEASE EDUCATION AND?REFERRAL CENTER
  • ALZHEIMER'S DISEASE GENETICS STUDY
  • ALZHEIMER'S DISEASE GENETICS?CONSORTIUM
  • NIA GENETICS OF ALZHEIMER'S DISEASE?DATA STORAGE SITE
  • ALZHEIMER'S DISEASE SEQUENCE PROJECT
  • INVESTIGATIONAL NEW DRUG TOXICOLOGY PROGRAM
  • ALZHEIMER'S DISEASE NEUROIMAGING?INITIATIVE
  • GENOME-WIDE ASSOCIATION STUDIES
  • ACCELERATING MEDICINES PARTNERSHIP-ALZHEIMER'S DISEASE
  • AD TRANSLATIONAL INITIATIVES
  • THE DOMINANTLY INHERITED ALZHEIMER NETWORK
  • CLINICAL TRIALS
  • ALZHEIMER'S PREVENTION INITIATIVE
  • ARIZONA ALZHEIMER'S CONSORTIUM
  • PHARMACEUTICAL RESEARCH AND?MANUFACTURERS OF AMERICA
  • ADVISORY COUNCIL ON ALZHEIMER'S?RESEARCH, CARE, AND SERVICES
  • ALZHEIMER'S DRUG DISCOVERY FOUNDATION
  • ALZHEIMER'S ASSOCIATION
  • ALZHEIMER'S FOUNDATION OF AMERICA
  • ALZFORUM
  • INTERNATIONAL SOCIETY TO ADVANCE ALZHEIMER'S RESEARCH AND TREATMENT
  • ALZHEIMER'S IMPACT MOVEMENT
  • RESEARCHERS AGAINST ALZHEIMER'S/USAGAINST ALZHEIMER'S
  • SOCIAL MEDIA
  • 4 - Current Medications for the Treatment of Alzheimer's Disease: Acetylcholinesterase Inhibitors and NMDA Receptor Antagonist
  • INTRODUCTION
  • ACETYLCHOLINESTERASE INHIBITORS
  • PRACTICAL USE OF ACETYLCHOLINESTERASE INHIBITORS
  • NMDA ANTAGONIST USE
  • TREATMENT GUIDELINES AND DISEASE MANAGEMENT
  • TREATMENT DISCONTINUATION
  • 5 - Physicochemical Properties for Potential Alzheimer's Disease Drugs
  • INTRODUCTION
  • THE BLOOD-BRAIN BARRIER
  • PHYSICOCHEMICAL PROPERTIES OF ALZHEIMER'S DISEASE DRUGS
  • DRUG DELIVERY
  • CONCLUSIONS
  • 6 - Receptor Targets in Alzheimer's Disease Drug Discovery
  • INTRODUCTION
  • G PROTEIN-COUPLED RECEPTORS
  • Histaminergic Receptors
  • Serotonergic Receptors
  • Adrenergic Receptors
  • Cannabinoid Receptors
  • GABAB Receptors
  • Muscarinic Cholinergic Receptors
  • KINASES/ENZYMES
  • Acetylcholinesterase
  • Protein Kinases
  • Phosphodiesterase Enzymes
  • HMG-CoA Reductase
  • Histone Deacetylase
  • Monoamine Oxidase
  • IONOTROPIC CHANNELS
  • IONOTROPIC GLUTAMATE RECEPTORS
  • AMPA Receptors
  • N-Methyl-d-Aspartate Receptors
  • Kainate Receptors
  • CHOLINERGIC RECEPTORS
  • GABAA RECEPTORS
  • 5-HT3 RECEPTORS
  • CATION CHANNELS
  • HORMONE RECEPTORS
  • Steroid Hormones
  • Selective Estrogen-Receptor?Modulator
  • Nerve Growth Factor
  • POLYPHARMACOLOGY
  • CONCLUSIONS
  • 7 - Amyloid ß Hypothesis in the Development of Therapeutic Agents for Alzheimer's Disease
  • INTRODUCTION
  • EVOLUTION OF THE AMYLOID HYPOTHESIS
  • Genetic Evidence: Risk Alleles for Familial and Sporadic AD
  • APP
  • Presenilins
  • APOE4
  • Evidence of Aß Peptide's Role in Neurotoxicity
  • The Interplay of Aß and Tau Protein
  • DISEASE-MODIFYING THERAPEUTIC?APPROACHES
  • Inhibitors of Aß Aggregation
  • a-Secretase Inducers/Activators
  • ß-Secretase Inhibitors
  • PEPTIDOMIMETIC BACE-1 INHIBITORS
  • SMALL MOLECULE BACE-1 INHIBITORS
  • ?-Secretase Inhibitors and Modulators
  • Aß Peptide Immunotherapy
  • DISCUSSION
  • CONCLUSIONS
  • 8 - Tau Proteins
  • INTRODUCTION
  • TAU PROTEIN
  • AMYLOID BETA
  • AMYLOID BETA, TAU, AND SYNAPTIC?PLASTICITY: AN INTIMATE RELATIONSHIP
  • THE THERAPEUTIC TARGET
  • DISCUSSION AND FUTURE PERSPECTIVES
  • FINANCIAL AND COMPETING INTERESTS?DISCLOSURE
  • Acknowledgments
  • 9 - CHOLESTEROL AND FAT METABOLISM IN ALZHEIMER'S DISEASE
  • CHOLESTEROL AND FAT METABOLISM IN ALZHEIMER'S DISEASE
  • LIPIDOMICS AS A STRONG TOOL IN DECIPHERING THE ROLE OF LIPID MOIETIES IN AD
  • PLASMA MEMBRANE MICRODOMAIN (LIPID RAFTS) AND AD
  • CHOLESTEROL AND LIPID RAFTS MODULATE APP PROCESSING AND A? MOIETIES GENERATION
  • EXCITOTOXICITY-INDUCED LIPID ALTERATION:?A POTENTIAL LINK BETWEEN CHOLESTEROL?AND AD
  • PATHOLOGICAL ACTIVATION OF NEURONAL SREBP1: A COMMON DENOMINATOR IN NEURODEGENERATIVE DISEASES
  • Acknowledgments
  • 10 - Mitochondria as a Therapeutic Target for the Treatment of Alzheimer's Disease
  • INTRODUCTION
  • CURRENT TREATMENT FOR ALZHEIMER'S?DISEASE
  • MITOCHONDRIAL ENERGY METABOLISM?AND OXIDATIVE STRESS
  • MITOCHONDRIAL DYSFUNCTION IN AD
  • A?-INDUCED MITOCHONDRIAL DYSFUNCTION?IN AD
  • TARGETING PREP OR CYPD FOR PREVENTING?OR TREATING AD
  • PreP as a Potential AD Target
  • CypD as a Potential AD Target
  • INSIGHTS AND FUTURE
  • ABBREVIATIONS
  • Funding
  • 11 - Simple In Vivo Models of Alzheimer's Disease
  • INTRODUCTION
  • CAENORHABDITIS ELEGANS
  • Disease-Linked Mutations and Neurodegeneration
  • Amyloid Peptide Precursor Protein
  • Presenilins
  • Tau
  • Metal-Induced Neurodegeneration
  • Pharmaceutical Testing
  • DROSOPHILA MELANOGASTER
  • Disease-Linked Mutations and Neurodegeneration
  • Amyloid Peptide Precursor Protein
  • Presenilins
  • Tau
  • Apolipoprotein E4
  • Metal-Induced Neurodegeneration
  • Pharmaceutical Testing
  • DANIO RERIO
  • Disease-Linked Mutations and Neurodegeneration
  • Amyloid Peptide Precursor Protein
  • Presenilins
  • Tau
  • Apolipoprotein E4
  • Pharmaceutical Testing
  • CONCLUSIONS
  • 12 - Rodent Models for Alzheimer's Disease in Drug Discovery
  • INTRODUCTION
  • OVERVIEW OF ANIMAL MODELS?OF ALZHEIMER'S DISEASE
  • GENETICALLY MODIFIED RODENT MODELS?OF ALZHEIMER'S DISEASE
  • INTEGRATION OF ALZHEIMER'S DISEASE?MODELS AND BEHAVIORAL ANALYSES?IN DRUG DISCOVERY
  • CONCLUSIONS
  • 13 - Alzheimer's Disease Drugs in Clinical Trials
  • INTRODUCTION
  • 14 - Nonpharmacological Treatment Approaches
  • INTRODUCTION
  • NONPHARMACOLOGICAL INTERVENTIONS AND COGNITIVE RESERVE
  • Pathogenic Mechanisms of Cognitive Impairment in Alzheimer's?Disease
  • Cognitive Reserve Hypothesis
  • Cognitive Training
  • Lifestyle Influences on Alzheimer's?Disease
  • Exercise
  • Diet
  • Vascular Risk
  • Diabetes
  • Sleep
  • NONPHARMACOLOGICAL INTERVENTIONS AND NEUROPSYCHIATRIC SYMPTOMS
  • Environmental Modifications
  • Communicative Strategies and Person-Centered Care
  • Sensory-Related Strategies
  • Activity-Based Strategies
  • CONCLUSION
  • Index
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • K
  • L
  • M
  • N
  • O
  • P
  • R
  • S
  • T
  • V
  • Back Cover

Dateiformat: EPUB
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat EPUB ist sehr gut für Romane und Sachbücher geeignet - also für "fließenden" Text ohne komplexes Layout. Bei E-Readern oder Smartphones passt sich der Zeilen- und Seitenumbruch automatisch den kleinen Displays an. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Dateiformat: PDF
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat PDF zeigt auf jeder Hardware eine Buchseite stets identisch an. Daher ist eine PDF auch für ein komplexes Layout geeignet, wie es bei Lehr- und Fachbüchern verwendet wird (Bilder, Tabellen, Spalten, Fußnoten). Bei kleinen Displays von E-Readern oder Smartphones sind PDF leider eher nervig, weil zu viel Scrollen notwendig ist. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Download (sofort verfügbar)

128,52 €
inkl. 19% MwSt.
Download / Einzel-Lizenz
ePUB mit Adobe DRM
siehe Systemvoraussetzungen
PDF mit Adobe DRM
siehe Systemvoraussetzungen
Hinweis: Die Auswahl des von Ihnen gewünschten Dateiformats und des Kopierschutzes erfolgt erst im System des E-Book Anbieters
E-Book bestellen

Unsere Web-Seiten verwenden Cookies. Mit der Nutzung dieser Web-Seiten erklären Sie sich damit einverstanden. Mehr Informationen finden Sie in unserem Datenschutzhinweis. Ok